These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 23528660)

  • 1. Tofacitinib: janus bifrons in ulcerative colitis treatment.
    Peyrin-Biroulet L; Danese S
    Gastroenterology; 2013 May; 144(5):1136-8. PubMed ID: 23528660
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
    Papp KA; Menter A; Strober B; Langley RG; Buonanno M; Wolk R; Gupta P; Krishnaswami S; Tan H; Harness JA
    Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
    Huang JF; Yafawi R; Zhang M; McDowell M; Rittenhouse KD; Sace F; Liew SH; Cooper SR; Pickering EH
    Ophthalmology; 2012 Jul; 119(7):e43-50. PubMed ID: 22607938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
    Tanaka Y; Maeshima K; Yamaoka K
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.
    Maeshima K; Yamaoka K; Kubo S; Nakano K; Iwata S; Saito K; Ohishi M; Miyahara H; Tanaka S; Ishii K; Yoshimatsu H; Tanaka Y
    Arthritis Rheum; 2012 Jun; 64(6):1790-8. PubMed ID: 22147632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
    Hanauer SB
    Aliment Pharmacol Ther; 2008 Mar; 27 Suppl 1():15-21. PubMed ID: 18307645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotine: does it have a role in the treatment of ulcerative colitis?
    Slyk MP; Frazee LA
    Am J Ther; 1997 Apr; 4(4):141-8. PubMed ID: 10423604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An experiment of acute fulminant severe ulcerative colitis in a 75- year-old male--a case report and a consideration of the surgical treatment of elderly patients with severe ulcerative colitis].
    Murata Y; Ueoka K; Suzuki T; Yura J; Kato F
    Nihon Geka Gakkai Zasshi; 1987 Feb; 88(2):216-21. PubMed ID: 3574280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
    Jakobovits SL; Jewell DP; Travis SP
    Aliment Pharmacol Ther; 2007 May; 25(9):1055-60. PubMed ID: 17439506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Take your medicine": nonadherence issues in patients with ulcerative colitis.
    Turnbough L; Wilson L
    Gastroenterol Nurs; 2007; 30(3):212-7; quiz 218-9. PubMed ID: 17568260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib for the treatment of rheumatoid arthritis.
    Zerbini CA; Lomonte AB
    Expert Rev Clin Immunol; 2012 May; 8(4):319-31. PubMed ID: 22607178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injecting drugs by a tube from appendix stump to colon may be a good method for dealing with refractory ulcerative colitis.
    Xu X; Cao Z; Li X; Tao D; Hu J; Yang C; Gong J
    Med Hypotheses; 2010 Apr; 74(4):631-3. PubMed ID: 19932937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tofacitinib Is the Right OCTAVE for Ulcerative Colitis.
    Pouillon L; Bossuyt P; Peyrin-Biroulet L
    Gastroenterology; 2017 Sep; 153(3):862-864. PubMed ID: 28757262
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical treatment of ulcerative colitis.
    Dalal L
    J Assoc Physicians India; 2007 Sep; 55():635-40. PubMed ID: 18051737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Autoimmune hemolytic anemia, infrequent complication of ulcerative colitis].
    Castellví Suaña JM; Perelló Juan A; Cervantes Arnau X; Guardiola Capón J; Baliellas Comellas C; Xiol Quingles X
    Rev Esp Enferm Dig; 1994 Dec; 86(6):908-11. PubMed ID: 7873267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
    Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
    Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.